BURLINGAME, Calif., Feb. 5 /PRNewswire/ -- BioSeek, Inc. today announced that Roy A. Whitfield has been elected executive chairman of the Company’s board of directors. Mr. Whitfield had joined BioSeek’s board of directors and served as a business advisor to the Company since November, 2005.
“Roy’s management experience and expertise in drug discovery and business development have been extraordinarily valuable to BioSeek thus far. We look forward to his continued leadership and guidance as executive chairman as we advance our internal drug discovery and development efforts and continue to secure corporate partnerships that capitalize upon our BioMAP(R) screening systems platform,” said Michael C. Venuti, Ph.D., CEO of BioSeek.
Roy Whitfield has over 20 years of management and governance experience in the biotechnology industry. Most recently, Roy served as CEO and Chairman of Incyte Corporation, a genomics company he co-founded in 1991. Incyte pioneered the commercialization of high throughput and information technology in pharmaceutical and medical research. At Incyte, Roy executed the first genomics initial public offering (IPO) and later raised over $700 million in financing. In 1997, he was named Northern California “Entrepreneur of the Year” for Life Sciences. Roy also serves on the boards of directors of Incyte Corporation, Nektar Therapeutics, Illumina and several private companies, and in the past served on the boards of Aurora Biosciences and the Biotechnology Industry Organization (BIO). Roy received a B.A. degree from Oxford University and an M.B.A. from Stanford University.
About BioSeek
BioSeek is improving the success rate of pharmaceutical research and development by integrating human biology from the early stages of drug discovery onward. The Company’s BioMAP(R) Systems incorporate predictive human cell-based disease models that generate uniquely informative activity signatures for each potential drug, driving the selection and development of new drug candidates. BioSeek is leveraging BioMAP(R) Systems technology in collaborations to enhance the productivity of its pharmaceutical partners’ pipelines, and in the Company’s internal programs to identify promising compounds for proprietary development in the fields of inflammation, cardiovascular diseases, autoimmune diseases, and related indications.
http://www.bioseekinc.com
CONTACT: Michael Venuti, Ph.D., CEO of BioSeek, Inc., +1-650-552-0754; or
Jennifer Greenleaf of MacDougall Biomedical Communications for BioSeek,
Inc., +1-781-235-3060
Web site: http://www.bioseekinc.com/
